tetano
Editor, Senior Moderator
Clin Dermatol
. Nov-Dec 2021;39(6):1083-1087.
doi: 10.1016/j.clindermatol.2021.07.008. Epub 2021 Jul 17.
Impact of COVID-19 on patients with atopic dermatitis
Teresa Grieco[SUP] 1 [/SUP], Camilla Chello[SUP] 1 [/SUP], Alvise Sernicola[SUP] 2 [/SUP], Rovena Muharremi[SUP] 1 [/SUP], Simone Michelini[SUP] 1 [/SUP], Giovanni Paolino[SUP] 1 [/SUP], Giorgia Carnicelli[SUP] 1 [/SUP], Paolo Daniele Pigatto[SUP] 3 [/SUP]
Affiliations
Abstract
Data on the tolerability and response to biologic therapies for type 2 immune disorders in the context of coronavirus disease 2019 (COVID-19) are currently lacking. Our survey aimed at assessing the adherence of patients to dupilumab therapy and the risk of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. A total of 80 patients with atopic dermatitis treated with dupilumab completed a web-based survey. Of the 80 patients, 7 discontinued dupilumab owing to concerns and difficulties related to COVID-19. Our sample was highly susceptible to viral infection owing to the frequency of risk factors including living in high SARS-CoV-2 burden areas, such as in Northern Italy; having comorbidities, such as asthma, diabetes, and cardiovascular disease; and being of advanced age. Older patients in our sample are particularly exposed to the risk of COVID-19-related cytokine storm, triggered by excessive interleukin-4 production and type 2 immune response. One patient contracted SARS-CoV-2 infection without the progression of COVID-19 despite continuing scheduled dupilumab treatment. Because evidence on the appropriate management of biologic therapy in the setting of COVID-19 is lacking, the collection of clinical data from patients in treatment with dupilumab is a valuable addition to current clinical practice. Our survey provides a contribution to the understanding of the tolerability and response to dupilumab during COVID-19 and suggests a feasible and effective approach to patients being treated with biologics even when social distancing is required.
. Nov-Dec 2021;39(6):1083-1087.
doi: 10.1016/j.clindermatol.2021.07.008. Epub 2021 Jul 17.
Impact of COVID-19 on patients with atopic dermatitis
Teresa Grieco[SUP] 1 [/SUP], Camilla Chello[SUP] 1 [/SUP], Alvise Sernicola[SUP] 2 [/SUP], Rovena Muharremi[SUP] 1 [/SUP], Simone Michelini[SUP] 1 [/SUP], Giovanni Paolino[SUP] 1 [/SUP], Giorgia Carnicelli[SUP] 1 [/SUP], Paolo Daniele Pigatto[SUP] 3 [/SUP]
Affiliations
- PMID: 34920828
- DOI: 10.1016/j.clindermatol.2021.07.008
Abstract
Data on the tolerability and response to biologic therapies for type 2 immune disorders in the context of coronavirus disease 2019 (COVID-19) are currently lacking. Our survey aimed at assessing the adherence of patients to dupilumab therapy and the risk of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. A total of 80 patients with atopic dermatitis treated with dupilumab completed a web-based survey. Of the 80 patients, 7 discontinued dupilumab owing to concerns and difficulties related to COVID-19. Our sample was highly susceptible to viral infection owing to the frequency of risk factors including living in high SARS-CoV-2 burden areas, such as in Northern Italy; having comorbidities, such as asthma, diabetes, and cardiovascular disease; and being of advanced age. Older patients in our sample are particularly exposed to the risk of COVID-19-related cytokine storm, triggered by excessive interleukin-4 production and type 2 immune response. One patient contracted SARS-CoV-2 infection without the progression of COVID-19 despite continuing scheduled dupilumab treatment. Because evidence on the appropriate management of biologic therapy in the setting of COVID-19 is lacking, the collection of clinical data from patients in treatment with dupilumab is a valuable addition to current clinical practice. Our survey provides a contribution to the understanding of the tolerability and response to dupilumab during COVID-19 and suggests a feasible and effective approach to patients being treated with biologics even when social distancing is required.